Needham & Company LLC Raises Oculis (NASDAQ:OCS) Price Target to $40.00

Oculis (NASDAQ:OCS) had its price target upped by research analysts at Needham & Company LLC from $36.00 to $40.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 44.20% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on OCS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. Stifel Nicolaus boosted their price objective on shares of Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Chardan Capital reiterated a “buy” rating and issued a $51.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Lifesci Capital assumed coverage on shares of Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

Oculis Trading Up 0.1%

Oculis stock opened at $27.74 on Wednesday. Oculis has a one year low of $14.00 and a one year high of $30.68. The company’s fifty day moving average price is $26.03 and its two-hundred day moving average price is $21.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 4.47. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -12.22 and a beta of 0.29.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%. On average, analysts forecast that Oculis will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Oculis in the second quarter valued at about $393,000. Bosun Asset Management LLC acquired a new position in Oculis during the 2nd quarter worth about $378,000. Bank of America Corp DE grew its holdings in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. Finally, Woodline Partners LP increased its position in Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after acquiring an additional 33,265 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis News Roundup

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Privosegtor received Breakthrough Therapy designation for optic neuritis and Oculis is advancing registrational programs in optic neuropathies — a large addressable U.S. market (>$7B) if trials succeed. This is a material clinical/regulatory positive for OCS. Article Title
• Positive Sentiment: Topline readout for OCS-01 in diabetic macular edema (DIAMOND Phase 3) is on track for Q2 2026 — a near-term binary catalyst that could materially re‑rate the stock if positive. Article Title
• Positive Sentiment: Wall Street support increased: Needham and HC Wainwright raised price targets (to $40 and $44 respectively) and maintain buy ratings — these upgrades can attract investor interest and support higher valuations. Article Title
• Positive Sentiment: Significant institutional accumulation reported (multiple funds added large positions in Q4 2025), which can provide demand support into upcoming catalysts. Article Title
• Neutral Sentiment: Oculis is presenting at multiple investor conferences in March (Leerink Global Healthcare Conference, LifeSci Capital Biotech Forum) — increases management visibility and provides opportunities for Q&A but no direct clinical data. Article Title
• Neutral Sentiment: Company filed audited 2025 consolidated financial statements and MD&A with the SEC — increases transparency; separately, Oculis renewed a $100M ATM program (capital flexibility that can fund development but may dilute if used). Article Title
• Negative Sentiment: Quarterly results missed EPS estimates (reported ($0.51) vs. consensus ($0.43)); while revenue beat estimates, margins and ROE remain deeply negative — a reminder of biotech execution and cash‑burn risk until pivotal approvals. Article Title
• Negative Sentiment: Notifications show RSU vesting/settlement for a director — standard governance activity but adds modest share count pressure/short‑term dilution. Article Title

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.